Key recommendations from the latest EACS and DHHS guidelines for DESCOVY®▼ (emtricitabine / tenofovir alafenamide) are listed below, with links to the full publications.
Please click on the tabs below to find recommendations on how to prescribe DESCOVY®▼ (emtricitabine / tenofovir alafenamide). Full details of the information can be found in the DESCOVY® Summary of Product Characteristics.
The safety data for DESCOVY®▼ (emtricitabine / tenofovir alafenamide) is based on data from all phase 2 and 3 studies, involving >3,000 HIV-positive individuals receiving FTC/TAF.1
The clinical evidence to support DESCOVY®▼ (emtricitabine / tenofovir alafenamide) in combination with other antiretroviral agents for the treatment of HIV is based on studies conducted with FTC and TAF when given with boosted EVG as the fixed-dose combination tablet E/C/F/TAF,1-5 and data from a phase 3 trial in virologically suppressed adults with HIV infection. 6-8
DESCOVY® is a fixed-dose combination tablet containing emtricitabine (FTC) and tenofovir alafenamide (TAF). Together, they form a nucleoside reverse transcriptase inhibitor (NRTI) backbone.1,2